Answers are grounded in this paper and cite their sources.
Our findings suggest that NTRK3-MT can predict the prognosis of patients with LUAD treated by ICIs and that it may have clinical significance for immunotherapy.
No takes yet. Share an insight, caveat, or question.
Niu et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: